MedEvidence! Radio is a monthly live broadcast from WSOS 103.9 FM / 1170 AM with Kevin Geddings and Dr. Michael Koren from St. Augustine, Florida. This month's MedEvidence Radio discusses all the various viruses coming our way this season. We will dive into:RSV - Respiratory Syncytial VirusCOVIDFlu Developing virus strategy planVaccine effectsAntibody levelsDr. Michael Koren is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals. Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical Center. On a personal note, Dr. Koren has a life-long interest in history, technology, Public Health, and music. He has written two musical plays.More information and to Participate in Clinical Research Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow MedEvidence! on Social Media to discover the Truth Behind the Data.FacebookInstagramTwitterLinkedInPowered by ENCORE Research Group at www.ENCOREDOCS.comOriginal Air Date: October 26, 2022#MedEvidence #patientcare #clinicalresearch #clinicaltrials #research #RSV #COVID #Flu #coldplan
Featuring perspectives from Drs Danielle Brander, Matthew Davids, Anthony Mato and William Wierda, including the following topics: Front-Line Chronic Lymphocytic Leukemia (CLL; Standard-Risk Patients) — Anthony R Mato, MD, MSCE (0:00) CLL in 2022: Front-Line Therapy for Patients with High-Risk Disease — Danielle Brander, MD (28:50) Fixed-Duration Targeted Therapy for CLL — William G Wierda, MD, PhD (59:26) Novel Investigational Agents and Strategies for CLL — Matthew S Davids, MD, MMSc (1:13:11) CME information and select publications
Let us say: being a research site is no walk in the park. In this episode, Adam Larrabee, president of Rochester Clinical Research, talks about how a site runs sponsored clinical research and the challenges it has to face to achieve it. Every sponsor works differently, so there is a protocol to be followed when starting a trial to ensure its success. Adam discusses the process and its challenges, from pre-site qualification to the trial's execution. He talks about areas where there is room for improvement, like training and onboarding, protocol manuals, and patient enrollment. He also speaks about the site's relationship with sponsors and how it can affect the entire process for worse or for better. Tune in to this episode to learn how research sites operate when contracted for clinical trials by sponsors! Click this link to the show notes, transcript, and resources: outcomesrocket.health
Listen to today's 7-minute Live from the American Heart Association Conference as Dr. Koren tells us what's new in heart health. Join Dr. Michael Koren and Kevin Geddings each Monday as they give you the quick down-and-dirty truth behind the most recent medical data. Dr. Michael Koren is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals. Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical Center. On a personal note, Dr. Koren has a life-long interest in history, technology, Public Health, and music. He has written two musical plays.More information and to Participate in Clinical Research Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow MedEvidence! on Social Media to discover the Truth Behind the Data.FacebookInstagramTwitterLinkedInPowered by ENCORE Research Group at www.ENCOREDOCS.comOriginal Air Date: November 7, 2022#MedEvidence #heart #americanheartassociation #cardiohealth #cardiovasularresearch #LPa #hearthealth #clinicalresearch #clinicaltrials
Dr. Jason Galster is a recognized leader in hearing loss and cochlear implants. He currently serves as the Director of Clinical Research at Advanced Bionics, a company that offers advanced cochlear implants for adults and children alike. He's also an adjunct professor at Salus University and Nova Southeastern University. Starting his career in 1999 as a research assistant, Dr. Galster is known for his innovation and research in audiology. He refined his approach over the course of a decade at Starkey Hearing Technologies, working as the Senior Manager of Audiology Research. In this episode… Clinical guidelines have a greater effect on the culture of audiology than many people realize. Setting a high watermark and standards of practice gives clinics defined goals, and the thorough process of establishing guidelines ensures they are realistic and applicable. Now that they've been issued, the refining process begins. Dr. Jason Galster is a key figure in the audiology world and has worked with the American Academy of Audiology (AAA) to continue pushing clinical guidelines. The use of the current standards helps experts know what is working well and what needs further improvement. So what should people expect for the future of guidelines? In this episode of the ListenUp! Podcast, Dr. Mark Syms invites Dr. Jason Galster, the Director of Clinical Research at Advanced Bionics, back onto the show to talk about improving clinical guidelines. They go through cochlear implant reimbursement and how it has changed through research. They also discuss the differences in pediatric and adult guidelines, defining terminology, and what the future holds for the AAA.
This month on JHLT The Podcast, JHLT Digital Media Editor Van-Khue Ton, MD, takes over hosting duties to present two unique papers from the November issue of The Journal of Heart and Lung Transplantation. Listen now to hear study authors discuss their work, their studies, and next steps for their research. First, we welcome first author Megan M. Collins, MD, about her team's study from the University of Utah entitled “Attitudes & practices surrounding pregnancy post heart transplantation among pediatric providers.” Dr. Collins shares her journey from being an undergraduate economics major to her current career in pediatrics, including how strategy and game theory have helped her better understand her patients and thrive during her pediatric cardiology fellowship. The study itself is exceptionally important as more pediatric heart transplant recipients reach adulthood and become interested in family planning. The study consisted of confidential and voluntary web surveys of pediatric heart transplant doctors, exploring their behaviors and policies around pregnancy and family planning. Next, R. James White, MD, from the division of Pulmonary and Critical Care Medicine at the University of Rochester Medical Center, shares details on the study “Contemporary Risk Scores Predict Clinical Worsening in Pulmonary Arterial Hypertension – An Analysis of FREEDOM-EV.” Dr. White is the senior author on the study, and discusses how he became interested in risk scores for pulmonary arterial hypertension, including some of the exciting data that they reveal. Prior to this study, none of the event-driven trials in PAH had previously incorporated serial assessment of risk scores like hemodynamics, laboratory values, exercise tolerance, and symptoms at baseline. Using data from the FREEDOM-EV trial, the study retrospectively compared the discriminant power of 4 risk scores, REVEAL 2.0, REVEAL Lite 2, 4-strata COMPERA 2.0, and the non-invasive French risk assessment, in predicting patients' clinical worsening at baseline and at a 12-week follow up. You won't want to miss Dr. White's insights on this comparison! Follow along in the November issue at www.jhltonline.org/current, or, if you're an ISHLT member, log in at ishlt.org/journal-of-heart-lung-transplantation. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org. This episode of JHLT: The Podcast, but not the studies within, is sponsored by Altavant Sciences.
The clinical trials system is broken and needs to be fixed in a way that's simpler for everyone involved. In this episode, Ivan Jarry, co-founder, and CEO at ObvioHealth talks about using digital technology to tackle the inefficiencies in healthcare clinical research, decentralizing clinical trials with an easy and engaging patient-centric app. Ivan argues healthcare and clinical research space is a very antiquated, regulated industry and details how ObvioHealth is helping run studies more efficiently taking the processes directly to participants at home through technology. He explains how making assessments at home makes more people willing to participate and stay in the trial. He speaks of digital instruments and how their implementation can increase data accuracy and reduce measurement bias. Ivan talks about how ObvioHealth built tools to enable this type of research in different countries with different regulatory environments, taking into account elements like security, validation, and data hosting, allowing them to expand their reach. Tune in to this episode to learn about how bringing people processes with technology can make clinical research more efficient! Click this link to the show notes, transcript, and resources: outcomesrocket.health
Clinical research studies are increasing in numbers, they're getting more complex, and they must be executed in a very challenging, tight labor environment. These are some of the key drivers of decentralized programs that use technology to lessen the burden of requiring patients to be physically present in order to participate. Despite advances in IT, informed consent — the linchpin moment between recruiting and participation — remains a challenge. In this episode, Justin Mardjuki and Greg Kefer discuss why eConsent is so hard, and how modern conversational technology may finally connect the dots by making the consent process easy for patients, while also satisfying multiple regulatory and collaboration requirements that research initiatives require.
This episode features Dr. Shakira Henderson, Vice President Research Officer at UNC Health, Assistant Vice Chancellor - Clinical Research & Clinical Research Integration Officer at University of North Carolina at Chapel Hill. Here, she discusses her different roles at UNC, healthcare trends she is currently following, and more.
In Part 2 of our Hemophilia B episode, we spotlight research priorities into women with hemophilia B, novel therapies to treat people with hemophilia B, and we conclude the story of Alexei Nikolaevich, the last Tsesarevich of Russia. Contributors: Bethany Samuelson Bannow, MD Brian O'Mahony Kathaleen M. Schnur, MSW, LCSW Senior Advisor: Donna DiMichele, MD Episode Advisors (also contributors): Dr. Amy Shapiro Professor Jan Astermark Hosted by: Laurence Woollard Links to learn more: Brown A. "The Royal Disease and The Royal Collapse: Political Effects of Hemophilia in the Royal Houses of Europe." Honor Scholar Theses. 2017;63. [Online]. Available at: https://scholarship.depauw.edu/cgi/viewcontent.cgi?article=1063&context=studentresearch [Accessed 10 October 2022] Gualtierotti R, et al. Updates on novel non-replacement drugs for hemophilia. Pharmaceuticals 2022;15(10):1183. Doi: 10.3390/ph15101183 Hart DP, et al. International consensus recommendations on the management of people living with haemophilia B. Ther Adv Hematol 2022;13:1-22. Doi: 20406207221085202 Hoffman TA. "Bad Blood: Hemophilia and Its Detriment to the Russian Imperial Family." Young Historians Conference. 2022;8. [Online]. Available at: https://pdxscholar.library.pdx.edu/cgi/viewcontent.cgi?article=1244&context=younghistorians [Accessed 10 October 2022] Lannoy N, Hermans C. The ‘royal disease' – haemophilia A or B? A haematological mystery is finally solved. Haemophilia 2010;16:843-47. Doi: 10.1111/j.1365-2516.2010.02327.x Nathwani A, et al. Liver gene therapy. Hum Gene Thur 2022;33:17-18. Doi: 10.1089/hum.2022.169 O'Donovan M, et al. Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life. Res Pract Thromb Haemost 2021;5(7):e12602. Doi: 10.1002/rth2.12602 Peeling S. Russo-Japanese War. International Encyclopaedia of the First World War. 1914-1918. [Online]. Available at: https://encyclopedia.1914-1918-online.net/article/russo-japanese_war [Accessed 10 October 2022] Potts WTW. Royal haemophilia. J Biol Educ 1996;30(3):207-17. DOI: 10.1080/00219266.1996.9655504 Price KD. "Diary of Nicholas II, 1917-1918, an annotated translation." Graduate Student Theses, Dissertations, & Professional Papers. 1966;2065. [Online]. Available at: https://scholarworks.umt.edu/cgi/viewcontent.cgi?article=3084&context=etd [Accessed 10 October 2022] Radcliffe J. “Rasputin and the Fragmentation of Imperial Russia.” Young Historians Conference. 2017;14. [Online]. Available at: https://pdxscholar.library.pdx.edu/younghistorians/2017/oralpres/14/ [Accessed 10 October 2022] Show Notes: Presenting Sponsor: Sanofi Subscribe to the Global Hemophilia Report Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on Twitter Global Hemophilia Report on Facebook Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook BloodStream on Twitter
Part 2 to the Leading with Vulnerability episode, Mo and Kizzle dive a little deeper into the effects of social media as it relates to being a well known figure with a platform; and why social media should be taken seriously instead of being seen as a "false reality." Mo and Kizzle also discuss "Lived experience" vs. "Clinical Research" and how the differences between the two have an effect on Black men and other individuals when it comes to seeking out Mental Health Treatment and Resources.
At Parexel, we are committed to improving patient's lives through clinical research. Within Parexel FSP — a division of Parexel — we fulfill key clinical development roles through functional service outsourcing models across a variety of disciplines for leading pharmaceutical sponsors. This includes finding the best candidates for vitally important CRA positions. To explore how Parexel FSP meets sponsor needs while creating rewarding career opportunities for talented clinical research professionals, Host Mrs. Jan Back, Recruitment Marketing Manager, Parexel FSP, speaks with Nannette Penny, Director, FSP Operations, and Alex Raines, Senior Executive Clinical Recruiter. The trio discuss how working for an FSP client differs from supporting a full-service client engagement, how the recruitment process works at Parexel FSP, the current career opportunities available for CRAs, and resources available to candidates interested in building an impactful career with a better quality of life. Key Takeaways: [:51] In her role as Director, Nannette oversees all recruitment and sourcing activities for a key client. [2:34] In his role as a Senior Executive Recruiter, Alex is responsible for finding, interviewing, and extending offers to candidates. [3:44] Nannette explains how the FSP model differs from full-service client engagement from a candidate's perspective. [5:50] Roles and responsibilities of a CRA in FSP on a typical day. [7:33] In the clinical research global landscape, a mismatch exists in available talent and the current increased demand for CRAs. [9:18] Alex shares the characteristics he looks for when seeking out CRA candidates. [10:38] The benefits and opportunities available when working with Parexel in an FSP. [11:59] Current CRA positions available and common contract terms. [13:40] How candidates can contact a Clinical Recruiter at Parexel FSP. [14:23] Nannette and Alex share their first-hand employee feedback about working at Parexel FSP. How to find out more: Visit: Parexel's Functional Service Provider Career Website Connect with: Alex Raines on LinkedIn Explore: Current CRA positions available at Parexel
In today's episode of Lady Scientist Podcast, Jocelynn chats with Yolanda Hagar, Associate Director of Bioinformatics and Clare Paterson, Director of Clinical Research, both at SomaLogic. Somalogic was founded in 2000 with the goal of improving the well-being and quality of life of every individual by transforming how diseases were detected, diagnosed and managed. Built on decades of aptamer research, SomaLogic scientists developed a ground-breaking proteomics technology that overcomes the significant challenges of existing protein measurements. Clare and Yolanda share their career journeys and the unique working environment, a collaboration of minds and expertise!Learn more about Somalogic: https://somalogic.com/Yolanda's LinkedIn: https://www.linkedin.com/in/yolanda-hagar-9076b7137/Clare's LinkedIn: https://www.linkedin.com/in/clare-paterson-81627556/Subscribe to Lady Scientist Podcast wherever you listen to podcasts!
Dr. Chirag Shah is the Director of Clinical Research and Breast Radiation Oncology in the Department of Radiation Oncology at the Cleveland Clinic. He joins the Butts & Guts podcast to discuss recurrent breast cancer. Listen to learn more about the symptoms of breast cancer recurrence, when to seek medical attention, available treatment options, and other important information to know about this disease.
Welcome to our first special episode on Sleep Tech Appreciation Week! This episode is brought to you by React Health, formerly 3B Medical. Please check them out at https://3bproducts.com/ We open this week with the AAST President, Laree Fordyce! Laree is an experienced Clinical Educator in Sleep Technology with a demonstrated history of working in the hospital & health care industry. Skilled in Accreditation, Clinical Research, Medical Education, Medical Devices, and Pediatrics. Strong healthcare services professional with a Associate's degree focused in Electroneurodiagnostic/Electroencephalographic Technology/Technologist from British Columbia Institute of Technology / BCIT. Check out our Facebook/ LinkedIn posts for a special discount code on the AAST site for our listeners and viewers! Credits: Intro music: Pierce G Mann Audio and Video: Diego R Mann
Celebrating 5 years of TopMedTalk at 'Anesthesiology'; the Annual General Meeting of the Amercan Society of Anesthesiologists. This piece is presented by Desiree Chappell, Monty Mythen and Sol Aronson with their guest Davinder Ramsingh, Vice President of Clinical Research and Development at Butterfly Network and Professor of Anesthesiology at Loma Linda Medical Center. For more information go to: https://www.butterflynetwork.com/ A popular contributor to TopMedTalk you can hear more from Davinder in our extensive podcast archive here: https://www.topmedtalk.com/live-from-boston-asa-2017-enhanced-recovery-and-protocolised-care-in-cardiac-surgery/ Here: https://www.topmedtalk.com/asa-2018-san-francisco-point-of-care-ultrasound-pocus/ And here: https://www.topmedtalk.com/sca-davinder-ramisingh/ TopMedTalk is very proud to be partnered with the American Society of Anesthesiologists® at ANESTHESIOLOGY® 2022. Now in our fifth year TopMedTalk is bringing you our most comprehensive and extensive coverage of the largest gathering of anesthesiologists in the world! This audio is presented to you "as live" - if you'd like to see our coverage as it happens go now to: https://live.topmedtalk.com/ TopMedTalk is provided to you for free; if you want to help support our work and help give these conversations a wider audience please like and subscribe (if and where possible) before sharing it on your social media. TopMedTalk can be found on YouTube here: https://www.youtube.com/channel/UC-HYQmeIwcFCYO1hoQ8jShQ We are on Twitter here: https://twitter.com/topmedtalk We are on LinkedIn here: https://www.linkedin.com/company/topmedtalk We are on Facebook here: https://www.facebook.com/TopMedTalk1/
A fresh spotlight is on clinical research on account of the COVID-19 pandemic. Katherine Vandebelt, Global Vice President of Innovation at Oracle, shares how she is innovating clinical research participation through inclusive, accessible, and human-centered practices. In this episode, Katherine highlights the challenges of recruitment and retention of clinical research participants. She reflects on the stress that arrives alongside health conditions, diagnoses, and deciding a treatment path. Katherine shares her people-oriented approach to innovation and acknowledges our aversion to change. (1:22) – Global VP of Innovation athttps://www.oracle.com/ ( Oracle) (3:30) – Getting to know patients (5:28) – The impact of Bill C-22 (8:50) – Reflecting the actual population (11:57) – Health advocates and connection (15:04) – Communication and knowledge-building (20:36) – Deciding focus areas of innovation (24:32) – Thinking about “when” (29:34) – Addressing change Katherine Vandebelt is the Global Vice President of Innovation at https://www.oracle.com/ (Oracle). Katherine's niche is in pharmaceutical clinical development and transforming organizations to meet aggressive financial and operational goals. She is also the host of https://thelatestdose.libsyn.com/ (The Latest Dose) podcast. Katherine earned a bachelor's degree in pharmacology and physiology at the University of Toronto. If you'd like to receive new episodes as they're published, please subscribe to Innovation and the Digital Enterprise in https://podcasts.apple.com/us/podcast/innovation-and-the-digital-enterprise/id1451753709?mt=2 (Apple Podcasts), https://podcasts.google.com/?feed=aHR0cHM6Ly9mZWVkcy50cmFuc2lzdG9yLmZtL2lubm92YXRpb24tYW5kLXRoZS1kaWdpdGFsLWVudGVycHJpc2U%3D (Google Podcasts), https://open.spotify.com/show/3fOSh73F3sjyK7TIMFSOc1?si=uRAeLNvjQjmbnFjzWIvMlg (Spotify) or wherever you get your podcasts. If you enjoyed this episode, please consider leaving a review in https://podcasts.apple.com/us/podcast/innovation-and-the-digital-enterprise/id1451753709?mt=2 (Apple Podcasts). It really helps others find the show. https://www.dante32.com/ (Podcast episode production by Dante32.)
This week's MedEvidence! podcast continues with episode 3 where we learn how medical truths are found. What is hypothesis testing, history of finding the truth through research and Dr. Koren's founding of the Jacksonville Center for Clinical Research. Dr. Michael Koren, is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals. Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital / Memorial Sloan-Kettering Cancer Center/ Cornell Medical Center.Rate, Review and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow MedEvidence! on Social Media to discover the Truth Behind the Data.FacebookInstagramTwitterLinkedInPowered by ENCORE Research Group at www.ENCOREDOCS.comOriginal Air Date: September 16, 2022#demandfordata #medevidence #confusingmedicalclaims #medicalnews #clinincalresearch #historyJCCR
Are placebo-free clinical trials the next normal? Nino da Silva thinks so. In this episode, he shares his views on trends in drug development and clinical research, including the integration of genetic data into drug development with synthetic control arms and the importance of data protection.Da Silva is an international leader in medical informatics, health care and business strategy. He is currently Deputy Managing Director at BC Platforms, a Singapore-based global data science solutions leader in personalized health, drug discovery and life sciences research.Guest host Antonio De Castro talks with da Silva about advancements in drug discovery and development by combining genetic data with phenotypic data. For example, synthetic control arms incorporate external health data into clinical trials to speed up drug development, reduce trial costs and address ethical concerns. Improved access to data from many research fields and the real world make the adoption of synthetic control arms possible. Da Silva explains the importance of trusted research environments (TRE) and trusted collaboration environments (TCE) in enabling highly dynamic research with analytics, while protecting citizens' data privacy. Also critical to this work is the ability to harmonize and make comparable data from multiple sources and geographies. Da Silva leaves us with his thoughts on the importance of diversity and representation in clinical trials and the role of the Asia Pacific region as a growing R&D hub for life sciences.All presentations represent the opinions of the presenter and do not represent the position or the opinion of SAS.
An inpatient stay for a clinical study can complicate the billing process – here are some real-world tips and strategies to help you ensure clear communication, optimize electronic health records, and much more.
Over the past few years, the use of liquid biopsy has improved the ability to detect biomarkers for non-small cell lung cancer. In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the current state of liquid biopsies with Dr. David Gandara, Professor of Medicine and Director of Thoracic Oncology at the University of California, Davis; Dr. Charu Aggarwal, the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania; and Dr. Christian Rolfo, Professor of Medicine at Mount Sinai in New York City and the Associate Director for Clinical Research in the Center for Thoracic Oncology at the Tisch Cancer Institute.
Let's admit it. The alpha men need help. Yes, there's the mindset, nutrition, exercise, recovery, and sleep, but sometimes, there's also the supplementation. Today, we have Dr. Stephen Anton joining us to talk about the Alpha Max Test 3D, an all-natural testosterone booster. Dr. Stephen Anton is a Professor and Chief of Clinical Research in the Department of Aging and Geriatric Research at the University of Florida. He is a well-established expert on the role that lifestyle factors have in influencing obesity, cardiovascular disease, and metabolic disease conditions. He co-authored the book, The Man Diet, a science-based guide to optimizing health and vitality for men. If you're over 40, 50, 60, 70, or 80 and are looking for the best supplement to help complete your overall health needs, tune in to find out what his recommendation is and why it's the best you can take for your age. “So many people are living with chronic stress that leads to elevated cortisol. When we stay in this chronic stress, that decreases the ability of the body to create testosterone and keep the testosterone levels lower than they need to be.” —Dr. Stephen AntonIn This Episode: How men's testosterone levels are different today from 2 decades agoWhat led Dr. Anton into the field of research, especially on the study of the best supplement for men over 40Why supplementation is importantWhat healthy aging means and how it impacts men's lifespanWhat studies revealed about the effects of testosterone supplementation on men Why it's important to address a person's metabolic healthIdentify the connection between our body composition, metabolic health, and testosterone levelsReasons why men are living with chronic stress and the effects of chronic stress on the male hormonesImportant compounds present in the testosterone supplement, Alpha Max Test 3DThe “normal” range versus the “alpha” range of testosterone levelsResources: Join the Over 40 Alpha Brotherhood for just $1 – click here to start todayUse Podcast10 to receive 10% off your order of Alpha Max Test 3D (All Natural Testosterone Boosting Powder – Cherry Flavour) – https://funksupplementshop.com/product/alpha-max-test-3d-ultimate-testosterone-booster/Connect with Dr. Stephen Anton:Website - https://drstephenanton.com/Facebook - http://www.facebook.com/drstephenanton/Instagram - https://www.instagram.com/drstephenanton/Connect with Funk Roberts: Website - https://www.over40alpha.com/ Instagram - https://www.instagram.com/funkrobertsfitnessSubscribe and Listen on iTuneshttps://podcasts.apple.com/ca/podcast/the-over-40-alpha-podcast/id1446632685 Listen to This Episode on Your Favourite Podcast Channelwww.over40alphapodcast.com
Brittany's LinkedIn: https://www.linkedin.com/in/brittany-sloan-062897ab/FULL uncut interview: https://www.youtube.com/watch?v=5Ju1QbmG-ioAshley's LinkedIn: https://www.linkedin.com/in/ashleymargo01/The University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/Text Me: (949) 415-6256My podcast is Random Musings From The Clinical Trials GuruListen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/dp/1090349521/...Text "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe Clinical Research Circle: https://www.youtube.com/channel/UCgOSm8EN_M7xf9Xfw1m778wMy TikTok: DanSfera
One of the most notable topics discussed at the 2022 American Academy of Ophthalmology Meeting in Chicago was new advancements in geographic atrophy (GA) treatment. A form of advanced age-related macular degeneration (AMD), there are no currently available treatments for the debilitating disease. In this episode of DocTalk, we spoke with Arshad Khanani, MD, Director of Clinical Research, Sierra Eye Associates, on the findings from the GATHER2 trial on avacincaptad pegol for the treatment of GA. Throughout our conversation, Khanani laid out the first-time efficacy results of the phase 3 trial and its patient population, the overall safety of the agent, and what it might mean to alleviate the biggest unmet need in retina today. We hope you enjoy. If you are interested in more content from AAO 2022 or our ophthalmology coverage, visit us at HCPLive.
This week, Patrick speaks to Heidi Rehm who is at the top of the field of genome interpretation and medical genetics. She has been a pioneering figure in the curation and sharing of rare genomic datasets across a federated exchange known as The Genome Aggregation Database or gnomAD.
Deputy Editor Dr. Salma Jabbour, Vice Chair of Clinical Research and Faculty Development and Clinical Chief in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey, hosts Dr. Matthias Guckenberger, Chairman and Professor of the Department of Radiation Oncology at the University Hospital Zurich and University of Zurich, discussing a new article from his European team, "Completeness of reporting oligometastatic disease characteristics in the literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature," and Dr. David Palma, Clinician Scientist II at the Ontario Institute for Cancer Research, Radiation Oncologist at the London Health Sciences Center, and Associate Professor at Western University, who was the supervising author on the 5-year update of the SABR-COMET trial, " Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) – Extended Long-Term Outcomes."
Hemophilia B is a rare inherited X-linked disorder characterized by a congenital anomaly in the factor IX gene leading to a variable deficiency in clotting factor IX. In this episode, we explore the known differences between Hemophilia B and Hemophilia A and discuss priority areas for further research into Hemophilia B. The episode also guides listeners on an entertaining journey through 19th and 20th century European monarchy and the unlikely role that hemophilia played in forever shaping Europe's governance! Contributors: Bethany Samuelson Bannow, MD Brian O'Mahony Kathaleen M. Schnur, MSW, LCSW Senior Advisor: Donna DiMichele, MD Episode Advisors (also contributors): Dr. Amy Shapiro Professor Jan Astermark Hosted by: Laurence Woollard Links to learn more: Brown A. "The Royal Disease and The Royal Collapse: Political Effects of Hemophilia in the Royal Houses of Europe." Honor Scholar Theses. 2017;63. [Online]. Available at: https://scholarship.depauw.edu/cgi/viewcontent.cgi?article=1063&context=studentresearch [Accessed 10 October 2022] Hoffman TA. "Bad Blood: Hemophilia and Its Detriment to the Russian Imperial Family." Young Historians Conference. 2022;8. [Online]. Available at: https://pdxscholar.library.pdx.edu/cgi/viewcontent.cgi?article=1244&context=younghistorians [Accessed 10 October 2022] Lannoy N, Hermans C. The ‘royal disease' – haemophilia A or B? A haematological mystery is finally solved. Haemophilia 2010;16:843-47. Doi: 10.1111/j.1365-2516.2010.02327.x Potts WTW. Royal haemophilia. J Biol Educ 1996;30(3):207-17. DOI: 10.1080/00219266.1996.9655504 Price KD. "Diary of Nicholas II, 1917-1918, an annotated translation." Graduate Student Theses, Dissertations, & Professional Papers. 1966;2065. [Online]. Available at: https://scholarworks.umt.edu/cgi/viewcontent.cgi?article=3084&context=etd [Accessed 10 October 2022] Radcliffe J. “Rasputin and the Fragmentation of Imperial Russia.” Young Historians Conference. 2017;14. [Online]. Available at: https://pdxscholar.library.pdx.edu/younghistorians/2017/oralpres/14/ [Accessed 10 October 2022] Funnell APW, Crossley M. Hemophilia B Leyden and once mysterious cis-regulatory mutations. Trends Genet 2014;30(1):18-23. Doi: 10.1016/j.tig.2013.09.007 Simioni P, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009;361(17):1671-5. Doi: 10.1056/NEJMoa0904377 Nogami K, et al. Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2). Haemophilia 2022;28(5):745-59. Doi: 10.1111/hae.14602 Thorland EC, et al. Anaphylactic response to FIX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999;5(2):101-5. Chitlur M, et al. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009;15(5):1027-31. Doi: 10.1111/j.1365-2516.2009.02039.x DiMichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009;15(1):320-8. Doi: 10.1111/j.1365-2516.2008.01880.x Astermark J, et al. The B-Natural Study – The outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia 2021;27(5):802-13. Doi: 10.1111/hae.14357 Iorio A, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med 2009;171(8):540-46. Doi: 10.7326/M19-1208 Soucie JM, et al. Occurance rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia 2020;26(3):487-93. Doi: 10.1111/hae.13998 Berntorp E, et al. Quality of life in a large multinational haemophilia B cohort (The B-Natural Study – Unmet needs remain. Haemophilia 2022;28(3):453-61. Doi: 10.1111/hae.14525 Kihlberg K, et al. Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study. Haemophilia 2021;27(3):366-74. Doi: 10.1111/hae.14299 Feng D, et al. Evidence of clinically significant extravascular stores of factor IX. Thromb Haemost 2013;11(12):2176-2178. Doi: 10.1111/jth.12421 DiMichele DM, et al. Severe and moderate haemophilia A and B in US females. Haemophilia 2014;20(2):e136-43. Doi: 10.1111/hae.12364 Buckner TW, et al. Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study. Eur J Haematol 2017;98:5-17. Doi: 10.1111/ejh.12854 Show Notes: Presenting Sponsor: Sanofi Subscribe to the Global Hemophilia Report Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on Twitter Global Hemophilia Report on Facebook Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook BloodStream on Twitter
Dr. Fox LinkedIn: https://www.linkedin.com/in/daniel-fox-mph-phd-3955b222/The University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/Text Me: (949) 415-6256My podcast is Random Musings From The Clinical Trials GuruListen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/dp/1090349521/...Text "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe Clinical Research Circle: https://www.youtube.com/channel/UCgOSm8EN_M7xf9Xfw1m778wMy TikTok: DanSfera
Hiroki's LinkedIn: https://www.linkedin.com/in/ellisbutterfield/Manchala's LinkedIn: https://www.linkedin.com/in/dhruvmanchala/Robert's LinkedIn: https://www.linkedin.com/in/robert-s-g-358b0868/The University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/Text Me: (949) 415-6256My podcast is Random Musings From The Clinical Trials GuruListen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/dp/1090349521/...Text "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe Clinical Research Circle: https://www.youtube.com/channel/UCgOSm8EN_M7xf9Xfw1m778wMy TikTok: DanSfera
For today's episode, I interviewed Anu Osinusi, Vice President of Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead. She talks about how Gilead is at the forefront of battling viral diseases as well as the solutions they are formulating to ensure that each and every person has access to treatments for future pandemics and to preserve global health across the globe. Who's The Guest? Anu Osinusi serves as the Vice President of Clinical Development at Gilead Sciences. As a clinician-researcher with more than 15 years of experience in drug development, liver diseases, infectious diseases, and global health, she is responsible for overseeing the Viral Hepatitis (Hep B, C, and D), Respiratory and Emerging (COVID-19, Ebola, RSV, and others) Viruses portfolio. Episode Sponsored By Gilead Episode Resources Connect with Arundhati Parmar email@example.com https://twitter.com/aparmarbb?lang=en https://medcitynews.com/ Connect with Anu Osinusi https://www.gilead.com/ https://www.linkedin.com/in/anu-osinusi-aoo Review, Subscribe and Share If you like what you hear please leave a review by clicking here Make sure you're subscribed to the podcast so you get the latest episodes. Click here to subscribe with Apple Podcasts Click here to subscribe with Spotify Click here to subscribe with Podbean Click here to subscribe with RSS
The successful integration of oral oncolytics into practice depends on collaboration of the multidisciplinary cancer care team to guide patients through treatment with optimal medical, financial, and psychosocial support. CANCER BUZZ spoke to Dr. Mazyar Shadman, MD, MPH, Associate Professor of Clinical Research at Fred Hutch in Seattle, WA. Hear as our expert describes process improvement strategies to successfully integrate oral oncolytics into practice, and highlights how patient goals can be included in treatment planning. Mazyar Shadman, MD, MPH Associate Professor – Clinical Research Division - Fred Hutch Associate Professor - Medical Oncology Division- University of Washington Attending Physician – Seattle Cancer Care Alliance Seattle, WA Resources: Blog: Integrating Oral Oncolytics into Chronic Lymphocytic Leukemia Practice Integrating Oral Oncolytics into Chronic Lymphocytic Leukemia (CLL) Practice The Role of Pharmacy to Help Manage Patients with Cancer on Oral Oncolytics
Clinical Research is not an individual sport, it is a team sport in which one variable affects every outcome. In this episode, Jennifer Byrne, CEO of Javara, talks about taking a different approach to clinical research, improving it, and changing the narrative it has been associated with so far. In their conversation, Jennifer speaks about what an IRO is and why this type of company is different from other pharmaceutical companies conducting research nowadays. She presents CRAACO as an approach to clinical research and its intentions by giving some examples of its application. She brings awareness to different issues that occur in clinical research, including mistrust, complexity in systems and protocols, transparency, and teamwork. For her, the future of clinical trials will be in patient-centricity, understanding centricity as including the patient as part of the team. Tune in to this episode to learn the hard things about clinical research and how to manage them! Click this link to the show notes, transcript, and resources: outcomesrocket.health
In this episode we sit down with Dr. Nicole Stevens, Director of Clinical Research, to talk about the brand new MetaPWR Blend. She'll discuss the details behind the MetaPWR Blend, the research and testing that's been done, as well as why that research is so important. This episode is sponsored by MetaPWR System, learn more about how you can get a free, exclusive copy of the doTERRA MetaPWR: The 3-Step System for Metabolic Health audiobook by purchasing a the MetaPWR System.
Since she started her role as the Director of Education at Brook Lane Behavioral Services Rachel Hull has been on a mission to reduce the use of restraint and seclusion. Rachel applied for a grant from the Alliance Against Seclusion and Restraint to participate in a training program in the Collaborative and Proactive Solutions approach from Lives in the Balance to help in her work to reduce the use of restraint and seclusion.Rachel Hull joined Brook Lane Behavioral Services as Director of Education in August 2020. She oversees two Type 1 Special Education Schools in the state of Maryland. Rachel received her Bachelor of Science from Marshall University, where she spent time and played Division 1 volleyball. Rachel received the 2012 Honors College Award for Outstanding Service in Psychology from Clinical Research conducted at Mildred Mitchel-Bateman Psychiatric Hospital. Rachel then earned a Master's Degree in School emphasized Psychology.Rachel began her education journey working in education as a teacher for self-contained students with the primary disability of Autism. She then spent six years at the Berkeley County Board of Education Special Education Office, where she provided intervention services, programming, and eligibility involvement for students in the specific category of Autism and Behavior Disorders. Rachel worked with therapeutic intervention practices and was a CPI trainer. She also trained specifically in CPI intervention for students with Autism. She assisted teachers in developing student-specific interventions and classroom therapeutic environments. Rachel also coordinated and developed district-wide 504 plans as local Title IX oversight.Rachel is currently set to graduate from Harvard University with her certificate in Advanced Educational Leadership in Spring 2023.Support the show
Josh's Youtube: https://www.linkedin.com/in/josh-bhatti-9aaa94252/The University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/Text Me: (949) 415-6256My podcast is Random Musings From The Clinical Trials GuruListen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/dp/1090349521/...Text "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe Clinical Research Circle: https://www.youtube.com/channel/UCgOSm8EN_M7xf9Xfw1m778wMy TikTok: DanSfera
Do you have advice that you've heard that you use on almost every single procedure? I do. And it came from today's guest, Dr. John Burgess. Dr. Burgess is the assistant Dean for Clinical Research at the University of Alabama at Birmingham as well as Director of the Graduate Biomaterials Program and was recently featured on the main stage at the Spear Summit 2022. But I heard John at the Spring Vedder society meeting some years back and some of the things he said have stayed with me to this day. It was a true pleasure to get to talk with John about what he does, how materials research should be done and how dentists can be better at understanding materials. How does someone get in to biomaterials research? Clinical research at LSU How to find unbiased information...how do we evaluate literature? Is the research measuring what they think it's measuring? Bevels on posterior composites? How do we test this? (spoiler alert: don't bevel occlusal margins) The best material is "abuse tolerant." How do patients get screened for clinical research? NCCLs (noncarious cervical lesions) and the controversy surrounding them New chemistry Read the instructions more often than you think you should! "Dentists don't read" Manufacturers take their instructions very seriously...you should, too. Burgess on zirconia Designing research equipment on a napkin Zirconia is very kind to the opposing when polished Cementing zirconia crowns Cement removal...he REALLY likes Panavia SA Universal Polish vs. glaze on zirconia (glaze facial on premolars) The power of a credible speaker and disclosure of honoraria Some links from the show: Dr. John Burgess' website Spear Practice Solutions Panavia SA Universal Axis by Kerr zirconia polishers Join the Very Dental Facebook group using the password "Timmerman," Hornbrook" or "McWethy." If you'd like to support the Very Dental Podcast Network then you should support our sponsors! Cosmedent has an amazing fall line up of continuing education! Coming up on September 22nd through the 23rd is our friend Dr. Artie Volker teaching “Composite Power 101!” Dr. Corky Willhite is offering his legendary “Ultimate Esthetics” course! Both courses have lots of hands on exercises and as always they're limited to 15 people which guarantees lots of individual time with instructors! Don't miss your chance to learn in the greatest classroom in dentistry with some legendary instructors using the best of materials! Go check it out at verydentalpodcast.com/CEE! -- Our friends at CAD-Ray want you to know that there has never been a better time to get into intraoral scanning! They sell and support all kinds of digital dentistry products from scanners, to printers and even cloud based software! For instance, the Medit i600 itraoral scanner is priced at just about $13,000! And if you didn't know, CAD-Ray now distributes 3Shape scanners and the amazing Trios 4 wireless just had a $10,000 price cut! It comes in under $25,000. And all these options come with CAD-Ray's unbeatable support! Go check it out at verydentalpodcast.com/cadray! -- If there is one thing that's changed the way I look at teeth the most, it's probably the headlight I use with my loupes. Our friends at Enova make amazing loupes and distribute Zumax dental microscopes, both the best you can buy. But the amazing, weightless and cordless Qubit, Quasar or Quantum headlights (all others are just toys) are the biggest game changer. But be careful…if you try one, you're going to buy one! Why haven't you checked out Enova Illumination yet? You can get a killer deal on all things Enova by using the Very Dental link you'll find at verydentalpodcast.com/Enova! -- Have you been looking at your supply bill lately? Prices are REALLY going up on all the things you use every day in your office. Our friends at Crazy Dental understand and are here to help! Very Dental listeners can get 10% off their orders from Crazy Dental by using coupon code “VERYDENTAL10”! Go check out their amazing catalog and save yourself 10% off of their already amazing prices at verydentalpodcast.com/crazy! -- If you're looking for a one stop dental marketing solution, then look no further than the Wonderist Agency. Wonderist can help you with branding and a killer website. They'll design ad campaigns no matter how you want to get your name out there. But maybe most importantly, they'll show you how your marketing plan is working! They have industry leading analytics that help you understand what works and what doesn't in your area and they'll help you spend your marketing dollar in the wisest way possible! Go check out the Wonderist Agency at verydentalpodcast.com/Wonderist!
Physician and Director of Clinical Research at Columbia University, Dr. Andrew Bomback, joins the show to discuss his latest book, “Long Days, Short Years: A Cultural History of Modern Parenting," and the difficulties parents face in the modern age.
Darshan's LinkedIn: https://www.linkedin.com/in/darshankulkarni/The University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/Text Me: (949) 415-6256My podcast is Random Musings From The Clinical Trials GuruListen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/dp/1090349521/...Text "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe Clinical Research Circle: https://www.youtube.com/channel/UCgOSm8EN_M7xf9Xfw1m778wMy TikTok: DanSfera
Chirag Shah, MD, co-director of Breast Radiation and Clinical Research in the Department of Radiation Oncology at Cleveland Clinic, joins the Cancer Advances podcast to discuss breast cancer recurrence. Listen as Dr. Shah discusses his research that was presented at the American Society of Clinical Oncology (ASCO) 2022 annual meeting to help patients that are at risk of recurrence.
For this month's episode, JHLT The Podcast explores two impactful studies from the October issue of The Journal of Heart and Lung Transplantation. The episode is hosted by Daniel R. Goldstein, MD, Editor-in-Chief of JHLT, who is joined by the JHLT Digital Media Editors. Listen now to hear study authors discuss their work, their studies, and next steps for their research. First, the editors speak with first author Michael Harhay, PhD (pictured left) and senior author Edward Cantu, MD (pictured right), about their study from the University of Pennsylvania entitled “Epidemiology, risk factors and outcomes of lung retransplantation: an analysis of the ISHLT Transplant Registry.” Dr. Goldstein and Erika Lease, MD, interview Drs. Harhay and Cantu about the study. The objective of the study was to leverage the ISHLT Thoracic Transplant registry using an updated cohort of patients that underwent lung retransplantation to obtain an updated summary of the epidemiology of lung retransplantation; to examine the importance of the time between primary transplantation and retransplantation on outcomes after retransplantation; and to identify risk factors of mortality following lung retransplantation. Next, we hear from Anne Dipchand, MD (pictured), Professor of Pediatrics and Pediatric Cardiologist at the Hospital for Sick Children in Toronto, Canada, who is senior author on the study, “Eplet matching in pediatric heart transplantation: The SickKids experience.” Dr. Goldstein and David Schibilsky, MD, discuss the study with Dr. Dipchand. This single-center retrospective study measured allograft survival in 77 patients while performing HLA typing, antigen mismatch, and eplet mismatch analysis, with the goal of comparing the molecular level HLA matching with antigen level HL matching in post-heart transplant outcomes in children. Follow along in the October issue at www.jhltonline.org/current, or, if you're an ISHLT member, log in at ishlt.org/journal-of-heart-lung-transplantation. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.
Pregnant women have consistently been underrepresented in clinical trials. With pregnancy studies posing significant risks to the mother and fetus, requiring extensive follow-up procedures, and potentially jeopardizing market approvals, many pharmaceutical companies avoid this demographic almost entirely. As a result, healthcare providers often struggle to access data regarding drug safety in pregnancy, preventing them from administering the best care possible. “Pregnant people make decisions in a vacuum of evidence. Very often, their healthcare providers don't know the evidence, so the women actually make the decision and take the risk that everyone else is ignoring. I think that has to stop,” says podcast guest Dr. Anna David, obstetrician and director of the University College London Institute for Women's Health. In this episode, host Deborah Borfitz speaks with David about the obstacles facing pregnant patients in today's medical landscape and the past and present strides made to increase their representation in clinical research. David also talks about her work creating the first standardized vocabulary for drug safety and maternal-fetal adverse events, how COVID-19 changed the industry's perspective regarding pregnancy studies, and the novel trials currently fostering change across the globe.Links from this episode: Clinical Research News University College London UCL EGA Institute for Women's Health Innovative Medicines Initiative ConcePTION Project Accelerating Innovation for Mothers International Council for Harmonisation Healthy Mum, Healthy Baby, Healthy Future Paediatric Investigation Plan (PIP) Maternal and Fetal Adverse Event Terminology
We recently lost the irreplaceable Dr. Art Epstein. In honor of his memory we wanted to relaunch the episode we had the privilege of doing with him last year. He was an incredible doctor, a pioneer for optometry and a man with the kindest heart. Please keep his family, friends an patients in your prayers.Here are a few words from Dr. Alan Glazier about Dr. Epstein: Art grew up in the Bronx, NY. He received his O.D. degree from SUNY where he also was the college's first resident in ocular disease.He co-founded Phoenix Eye Care and Dry Eye – OSD Center, serving as its Director of Clinical Research. He was an Adjunct Associate Professor at Midwestern University Arizona.He was a fellow of the AAO, a Distinguished Practitioner of the National Academies of Practice, Diplomate of the American Board of Certification in Medical Optometry and Past-Chair of the AOA Contact Lens & Cornea Section.Art was a prolific author who published many hundreds of articles, scientific papers and book chapters. He was a Contributing Editor for Review of Optometry and Executive Editor of Review of Cornea and Contact Lenses. He founded, and served as Chief Medical Editor of Optometric Physician™, the first and most widely read E-Journal in eyecare. Dr. Epstein was a reviewer for numerous clinical and scientific journals. Dr. Epstein presented in excess of 1,250 invited lectures on a variety of topics nationally and in more than 50 countries across the globe.Art cared deeply for the profession and his colleagues. He influenced so many optometrists; he was a passionate and impactful advocate for Optometry and left a positive, indelible mark. iMOM PodcastIf you need a mom friend right now, you've come to the right place. Listen on: Apple Podcasts Spotify
ASTCT Talks: Celebrating Advocacy Efforts, Overcoming Barriers and Addressing Inequity in Cellular Transplantation In this latest episode of ASTCT Talks, we celebrate National Hispanic Heritage Month as Dr. Jennifer Saultz talks with Dr. Eneida Nemecek to highlight her work and share her advocacy, passion and journey to becoming a medical director of clinical research. She explains her experiences as a Latina woman in the field of cellular therapy and transplantation, barriers Hispanic and marginalized groups face in cellular transplantation, inclusivity efforts for health equity, the value of mentor and sponsorship and more. About Dr. Jennifer Saultz Dr. Jennifer Saultz is an Assistant Professor of Medicine at Oregon Healthy & Science University and a member of the Adult Transplant and cellular therapy team. Her research focuses on the innate immune resistance signatures in AML. She is also a member of the ASTCT Content Committee. About Dr. Eneida Nemecek Dr. Eneida Nemecek is a Professor of Pediatrics and Medical Oncology and Medical director of Clinical Research at the Knight Cancer Institute-Oregon Health & Science University (OHSU) in Portland, Oregon. Her research focuses on bone marrow and cellular therapies, and health services research addressing disparities in access for underrepresented groups. She has served in leadership roles in steering committees for several NIH/NCI-funded cooperative groups. She has also held elected leadership positions as director, trustee or committee chair in multiple organizations including Be The Match/National Marrow Donor Program, Blood and Marrow Transplant Clinical Trials Network, the Pediatric Blood and Marrow Transplant Consortium, American Society of Transplant and Cellular Therapies, American Society of Hematology and Foundation for the Accreditation of Cellular Therapy.
Ovarian cancer can be very hard to detect and it is extremely deadly for women. Dr. Theresa Werner, Senior Director of Clinical Research at the Hunstman Cancer Institute joins the show to discuss a new “inhibitor” they are testing that can give women a fighting chance.See omnystudio.com/listener for privacy information.
This week's MedEvidence! podcast is a four-part series airing back-to-back this week on Medical Marijuana. Meet Dr. Charlie Booras, former Principal Investigator at Jacksonville Center of Clinical Research, and Baptist Primary Care physician who grew his practice into Booras MD as a tribute to his father after treating his ALS with medical cannabis as a medication. Dr. Michael Koren and Dr. Booras dive into the scientific basis for the efficacy of medical cannabis.You will learn:Florida Medical Marijuana Law and ProcessTHC vs. CBDHealth Benefits for Medical MarijuanaHistory of MarijuanaLearn more about Clinical ResearchLearn more about BoorasMDDr. Michael Koren, is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals. Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital / Memorial Sloan-Kettering Cancer Center/ Cornell Medical Center.Rate, Review and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow MedEvidence! on Social Media to discover the Truth Behind the Data.FacebookInstagramTwitterLinkedInPowered by ENCORE Research Group at www.ENCOREDOCS.comOriginal Air Date: July 8, 2022
When a new drug or device undergoes “first in human” experience, the primary focus is on participant safety. How will the drug or device interact with the human body? And will this interaction be safe? To answer these two questions, regulatory authorities around the world require medical product manufacturers to conduct Phase I, also known as early phase clinical trials. To learn more about the complexities in early phase clinical trials, I invited Dr. Oren Cohen, President of Clinical Pharmacology Services and Chief Medical Officer at Labcorp Drug Development on the show. Dr. Cohen has more than 30 years of healthcare experience which includes his work on clinical development. I hope you enjoy this conversation with Dr. Oren Cohen. Podcast Sponsor: This podcast episode is brought to you by Calyx. Calyx is a trusted name in medical imaging, having delivered imaging services to meet the needs of global biopharmaceutical sponsors and clinical research organizations for over 25 years. To learn more, visit calyx.ai
On this special edition of The Meaningful People Podcast, Rabbi Dr. Ben Epstein guides an extraordinary meditation experience for people in preparation for Rosh Hashana. Rabbi Dr. Benjy is an experienced psychologist who blends traditional Mindfulness-Based Cognitive Therapy (MBCT) with cognitive-behavioral, spiritual, and acceptance techniques. He is the author of Living in the Presence: A Jewish Mindfulness Guide to Everyday Life. In addition to his private practice and mindfulness seminars, he is the Director of Staff Development and Clinical Research for Camp Hasc. ____________________________________ This episode is brought to you by Touro University! To learn more about how you can excel at Touro University, Visit Touro.edu/more ____________________________________ This episode is brought to you by Bridge Credit Solutions! If you're looking for a reputable credit repair company that can clean your credit within 6-60 days or your money back, Bridge Credit Solutions is your choice. Serious Inquiries Only https://api.whatsapp.com/send?phone=12126602991&text=Hi,%20Im%20interested%20in%20more%20information.%20Saw%20on%20MM%20 ____________________________________ Subscribe to Meaningful Minute on WhatsApp: https://wa.me/15166687800?text=Please%20subscribe%20me%20to%20Meaningful%20Min Ute ____________________________________ Subscribe to our Podcast Apple Podcasts: https://apple.co/2WALuE2 Spotify: https://spoti.fi/39bNGnO Google Podcasts: https://bit.ly/MPPGooglePodcasts Or wherever Podcasts are available! Follow us on Instagram: https://instagram.com/meaningfulpeoplepodcast Like us on Facebook: https://bit.ly/MPPonFB Follow us on Twitter:https://twitter.com/MeaningfuPplPod Editor: Sruly Saftlas Podcast created by: Meaningful Minute For more info and upcoming news check out: https://MeaningfulPeoplePodcast.com #jew #jewish #podcast #frum #rabbi #frumpodcast #meaningfulpeople #torah #mitzvah #hashem #jewishmusic #jewishpodcast #israel #kumzitz #nachigordon #jewishpod
Aaron Mann, co-founder of the Clinical Research Data Sharing Alliance (CRDSA), joins the podcast to discuss the importance of unleashing the power of clinical research data. Aaron explains why he's optimistic about the potential of data sharing among sponsors to revolutionize trial design and improve patient recruitment – and why he believes patients really want their data to be shared. "The question that CRDSA is really involved with is what happens after the trial? We know patients want their data to be used to further the science. It's why they join the clinical trial in the first place."
Audible Bleeding editors Matt Chia and Wen Kawaji are joined by JVS Assistant Editor Dr. Paul Dimuzio and JVS Editor-in-Chief Dr. Thomas Forbes to discuss a recent article in the JVS. They're joined by Dr. Elizabeth Andraska, the first author of the paper discussing long-term followup after EVAR, available now in the August 2022 issue of the JVS. Find out how this paper can have an immediate impact on your patients, and hear insights directly from Dr. Andraska in this exciting episode! Link to “Longer follow-up intervals following endovascular aortic aneurysm repair are safe and appropriate after marked aneurysm sac regression” by Andraska et al.: https://doi.org/10.1016/j.jvs.2022.01.079 Show Guests: Dr. Elizabeth Andraska (@eandraska) is in her sixth year of training in the integrated vascular surgery residency at the University of Pittsburgh. She has a Masters in Clinical Research from the University of Michigan and has completed two years of dedicated research time at the University of Pittsburgh. She is excited to pursue a career in academic vascular surgery. Previous episode with Dr. Elizabeth Andraska on Getting Started with Basic Science in Vascular Surgery: https://www.audiblebleeding.com/getting-started-in-basic-science/ Previous episode with Dr. Thomas Forbes and Dr. Ron Dalman on the next chapter of the JVS: https://www.audiblebleeding.com/2022/06/14/interview-with-the-incoming-editors-of-the-jvs/ JVS Host Introductions: Dr. Paul Dimuzio (@pdimuziomd) is the William M. Measey Professor of Surgery, Director of the Division of Vascular and Endovascular Surgery at Thomas Jefferson University Hospital and Co-Director of the Jefferson Vascular Center in Philadelphia, as well as being one of the new Assistant Editors for the JVS. Dr. Thomas Forbes (@TL_Forbes) is the Surgeon-in-Chief and James Wallace McCutcheon Chair of the Sprott Department of Surgery at the University Health Network, Professor of Surgery at the University of Toronto, as well as being one of the new Editors-in-Chief for the JVS. Audible Bleeding Host Introductions: Dr. Wen Kawaji (@WenKawaji) is a general surgery resident at Medstar Health in Baltimore, MD. She is passionate about vascular, trauma, and critical care and recently completed a burn/surgical critical care fellowship at Johns Hopkins. Wen has been a loyal audible bleeding fan throughout residency and is excited to learn from and work with the podcast team. In her spare time, she enjoys traveling, food adventures, and puzzles. Dr. Matthew Chia (@chia_md) is in his final year of the integrated vascular surgery program at Northwestern University. He obtained his medical degree from the University of Illinois College of Medicine, and also holds a Master's in Health Services and Outcomes Research at Northwestern. Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and #jointheconversation.
Right now, it is all about finding what recharges us as nurses. This week's guest on the SONSIEL Podcast is Andrea Jaramillo, a hospice nurse, forest therapy guide, and nurse farmer. She talks with host Hiyam Nadel about finding what nursing means to you and designing a career that is sustainable for yourself and makes you happy. After suffering from burnout, Andrea took the time to rediscover herself as a nurse before coming back to the patients. She transitioned from labor and delivery to hospice and became interested in forest therapy and farming. She explains how forest therapy connects people with nature and their health gets better. She discusses food and why it's important to consider it, as a social determinant of health, where patients get their food, and what their options are. Tune in to this episode and get inspired to find what nursing means to you to better the care that we provide for our patients! Click this link to the show notes, transcript, and resources: outcomesrocket.health